Severe Immune‐Related Neurological Adverse Events Associated With Immune Checkpoint Inhibitor Treatment: A Retrospective Single‐Center Study [PDF]
ABSTRACT Background Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of various malignancies. The resulting activation of the immune system may lead to neurological immune‐related adverse events (n‐irAEs).
Anna Grisold +10 more
openaire +3 more sources
Demyelination of the central nervous system and peripheral neuropathy associated with sintilimab treatment for lung adenocarcinoma: a case report [PDF]
Background Immune checkpoint inhibitor (ICI) therapy unleashes the body’s natural immune system to fight cancer. Neurological immune-related adverse events (NirAEs) are rare but can be severe.
Haibo Deng +4 more
doaj +2 more sources
Consensus disease definitions for the spectrum of neurologic immune related adverse events. [PDF]
2647 Background: Expanding FDA-approved indications for immune checkpoint inhibitors in patients with cancer has resulted in both therapeutic success and immune related adverse events (irAEs). Neurologic irAEs (irAE-Ns) have an incidence of 1-12% and a high fatality rate relative to other irAEs.
Amanda C Guidon +5 more
+8 more sources
Neurological Immune-Related Adverse Events After COVID-19 Vaccination: A Systematic Review [PDF]
AbstractThe coronavirus disease 2019 (COVID‐19) pandemic has affected millions of individuals worldwide. The global scientific effort to design an effective vaccine against this virus has led to the development of several vaccine candidates. The expedited rollout of these vaccines has created some public distrust regarding the safety of these new ...
Ameena Shafiq +12 more
openaire +2 more sources
Camrelizumab-Induced Isolate Abducens Neuritis: A Rare Ophthalmic Immune-Related Adverse Events
Background: Anti-tumor immunotherapy with immune checkpoint inhibitors induces several immune-related adverse events. Camrelizumab-related isolate abducens neuritis is rare.
Yanli Hou +3 more
doaj +1 more source
A 63-year-old male with metastatic non-small cell lung cancer developed longitudinal extensive transverse myelitis (LETM) following two cycles of Pembrolizumab, an immune checkpoint inhibitor (ICI) targeting the programmed cell death receptor 1 (PD-1 ...
Salma Charabi +4 more
doaj +1 more source
Immunotherapy has become the standard of care for various cancer types. The widespread use of immune checkpoints inhibitors confronts us with a whole range of novel immune-related adverse events.
Xiaoxiao Wang +5 more
doaj +1 more source
Recently, immune checkpoint inhibitors (ICIs) have become the standard treatment option for patients with lung cancer, including small cell lung cancer (SCLC).
Chun-Chia Chen +3 more
doaj +1 more source
Neurotoxicity in the Era of Immune Checkpoint Inhibitors: A Case-Based Approach
Immune checkpoint inhibitors (ICIs) have transformed the field of cancer immunotherapy and led to substantial improvements in patient outcomes across various malignancies. Neurological toxicities arising from ICI treatment represent a heterogeneous group
Özkan ALAN +12 more
doaj +1 more source
High-dose interleukin-2 therapy related adverse events and implications on imaging
High-dose interleukin-2 (HDIL-2) therapy was initially approved by the U.S. Food and Drug Administration for metastatic renal cell carcinoma (mRCC) and metastatic melanoma.
Neal R. Shah +6 more
doaj +1 more source

